NCT06858345

Brief Summary

The pharmacological treatment strategy is then tailored to the underlying hemodynamic phenotype of each patient. That is, rather than applying a one-size-fits-all treatment for all patients, therapy is tailored to the specific characteristics of how the cardiovascular system functions in each patient (e.g., whether the problem is more related to blood volume, vascular resistance, cardiac output, etc.). The goal is to personalize therapy to more effectively treat hypertensive states of pregnancy.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 27, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 5, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2026

Completed
Last Updated

March 5, 2025

Status Verified

February 1, 2025

Enrollment Period

1 year

First QC Date

February 27, 2025

Last Update Submit

February 27, 2025

Conditions

Preeclampsia

Outcome Measures

Primary Outcomes (1)

  • Prolongation of at least one week of gestation in pregnancy complicated by hypertensive state of pregnancy with antihypertensive therapy guided by hemodynamic phenotypes

    Number of weeks of pregnancy

    Up to 40 weeks

Study Arms (1)

• Duration of gestation in pregnancy complicated by hypertensive state of pregnancy with antihyperte

• Duration of gestation in pregnancy complicated by hypertensive state of pregnancy with antihypertensive therapy guided by hemodynamic phenotypes

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Pregnant patients undergoing regular hospital follow-up

You may qualify if:

  • Age greater than or equal to 18 years
  • Women with singleton and twin pregnancies complicated by hypertensive states of pregnancy.

You may not qualify if:

  • Minors under 18 years of age.
  • Women with mental disabilities.
  • Major congenital fetal anomaly.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

HCUVA

El Palmar, Murcia, 30120, Spain

RECRUITING

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-InducedPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Central Study Contacts

Catalina de Paco Matallana, MD

CONTACT

968369500katy.depaco@gmail.com

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 27, 2025

First Posted

March 5, 2025

Study Start

January 1, 2025

Primary Completion

January 15, 2026

Study Completion

January 15, 2026

Last Updated

March 5, 2025

Record last verified: 2025-02

Locations

ES(1)